Market Cap | 4.26K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -90.29M | Forward P/E | 0.00 | EPS next Y | - | 50D Avg Chg | 216.00% |
Sales | 1.1M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -88.00% |
Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
Recommedations | 4.00 | Quick Ratio | 1.33 | Shares Outstanding | 42.62M | 52W Low Chg | 900.00% |
Insider Own | - | ROA | -99.93% | Shares Float | 42.45M | Beta | 36.45 |
Inst Own | 0.02% | ROE | -580.57% | Shares Shorted/Prior | 2.34M/2.16M | Price | 0.00010 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,149 | Target Price | - |
Oper. Margin | -3,974.39% | Earnings Date | - | Volume | 655 | Change | 0.00% |
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Chardan Capital | Neutral | Apr 4, 22 |
Chardan Capital | Buy | Jan 31, 22 |
Chardan Capital | Buy | Nov 12, 21 |
JMP Securities | Market Outperform | Nov 3, 21 |
Morgan Stanley | Underweight | Oct 19, 21 |
Morgan Stanley | Equal-Weight | Mar 8, 21 |
Piper Sandler | Overweight | Feb 9, 21 |
Morgan Stanley | Equal-Weight | Jan 19, 21 |
JMP Securities | Outperform | Dec 23, 20 |